{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:54:20Z","timestamp":1787979260858,"version":"build-2784847793"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["2022-I2M-1-006"],"award-info":[{"award-number":["2022-I2M-1-006"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.lfs.2023.122377","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T13:35:22Z","timestamp":1703079322000},"page":"122377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Effect of chemotherapy in tumor on coronary arteries: Mechanisms and management"],"prefix":"10.1016","volume":"338","author":[{"given":"Chengqing","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lfs.2023.122377_bb0005","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.lfs.2023.122377_bb0010","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an international cardio-oncology society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur. Heart J."},{"issue":"48","key":"10.1016\/j.lfs.2023.122377_bb0015","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.lfs.2023.122377_bb0020","first-page":"1004","article-title":"Chemotherapy-related anatomical coronary-artery disease in lung cancer patients evaluated by coronary-angiography SYNTAX score","volume":"114","author":"Yang","year":"2020","journal-title":"Arq. Bras. Cardiol."},{"key":"10.1016\/j.lfs.2023.122377_bb0025","article-title":"Treatment-related coronary disorders of fluoropyrimidine administration: a systematic review and meta-analysis","volume":"13","author":"Lu","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.lfs.2023.122377_bb0030","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/annonc\/mdu055","article-title":"Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk","volume":"25","author":"Lestuzzi","year":"2014","journal-title":"Ann. Oncol."},{"issue":"30","key":"10.1016\/j.lfs.2023.122377_bb0035","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lfs.2023.122377_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002916","article-title":"Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem","volume":"9","author":"Poels","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.lfs.2023.122377_bb0045","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/0284186X.2019.1711164","article-title":"Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer","volume":"59","author":"Dyhl-Polk","year":"2020","journal-title":"Acta Oncol."},{"issue":"8","key":"10.1016\/j.lfs.2023.122377_bb0050","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.2000.18.8.1725","article-title":"Cardiovascular morbidity in long-term survivors of metastatic testicular cancer","volume":"18","author":"Meinardi","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lfs.2023.122377_bb0055","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4103\/0973-1482.103530","article-title":"Acute non-ST elevation myocardial infarction following paclitaxel administration for ovarian carcinoma: a case report and review of literature","volume":"8","author":"Gupta","year":"2012","journal-title":"J. Can. Res. Ther."},{"issue":"5","key":"10.1016\/j.lfs.2023.122377_bb0060","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/oxfordjournals.eurheartj.a062542","article-title":"Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer","volume":"9","author":"Stefenelli","year":"1988","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.lfs.2023.122377_bb0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol."},{"issue":"12","key":"10.1016\/j.lfs.2023.122377_bb0070","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","article-title":"Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lfs.2023.122377_bb0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.critrevonc.2014.04.004","article-title":"Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis","volume":"92","author":"Qi","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"17","key":"10.1016\/j.lfs.2023.122377_bb0080","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","article-title":"Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis","volume":"103","author":"Amir","year":"2011","journal-title":"J. Nat. Cancer Inst."},{"issue":"3","key":"10.1016\/j.lfs.2023.122377_bb0085","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bju.12905","article-title":"Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer","volume":"116","author":"Ziehr","year":"2015","journal-title":"BJU Int."},{"issue":"29","key":"10.1016\/j.lfs.2023.122377_bb0090","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1200\/JCO.21.01808","article-title":"Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors","volume":"40","author":"Laenens","year":"2022","journal-title":"JCO"},{"issue":"24","key":"10.1016\/j.lfs.2023.122377_bb0095","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.lfs.2023.122377_bb0100","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and Cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.lfs.2023.122377_bb0105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaccao.2021.11.008","article-title":"Cardiovascular disease among patients with AML and CHIP-related mutations","volume":"4","author":"Calvillo-Arg\u00fcelles","year":"2022","journal-title":"JACC CardioOncol."},{"issue":"6","key":"10.1016\/j.lfs.2023.122377_bb0110","doi-asserted-by":"crossref","first-page":"8396","DOI":"10.1002\/jcp.27752","article-title":"Clonal hematopoiesis: genes and underlying mechanisms in cardiovascular disease development","volume":"234","author":"Haybar","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"6","key":"10.1016\/j.lfs.2023.122377_bb0115","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacbts.2018.06.005","article-title":"Role of endothelium in doxorubicin-induced cardiomyopathy","volume":"3","author":"Luu","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2023.122377_bb0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1042\/CS20200305","article-title":"Cardiotoxic effects of angiogenesis inhibitors","volume":"135","author":"Dobbin","year":"2021","journal-title":"Clin. Sci. (Lond.)"},{"issue":"4","key":"10.1016\/j.lfs.2023.122377_bb0125","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1161\/HYPERTENSIONAHA.117.10490","article-title":"VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes","volume":"71","author":"Neves","year":"2018","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.lfs.2023.122377_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115686","article-title":"Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes","volume":"10","author":"Focaccetti","year":"2015","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.lfs.2023.122377_bb0135","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.yjmcc.2012.01.022","article-title":"Cancer therapy modulates VEGF signaling and viability in adult rat cardiac microvascular endothelial cells and cardiomyocytes","volume":"52","author":"Chiusa","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122377_bb0140","article-title":"Coronary vasospasm induced by cisplatin for seminoma","volume":"8","author":"S","year":"2019","journal-title":"Clin. Case Rep."},{"issue":"2","key":"10.1016\/j.lfs.2023.122377_bb0145","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/cvr\/cvab053","article-title":"Coronary microcirculation damage in anthracycline cardiotoxicity","volume":"118","author":"Gal\u00e1n-Arriola","year":"2022","journal-title":"Cardiovasc. Res."},{"issue":"4","key":"10.1016\/j.lfs.2023.122377_bb0150","doi-asserted-by":"crossref","first-page":"H705","DOI":"10.1152\/ajpheart.00370.2019","article-title":"Detrimental effects of chemotherapy on human coronary microvascular function","volume":"317","author":"Hader","year":"2019","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"21","key":"10.1016\/j.lfs.2023.122377_bb0155","article-title":"Cardiovascular disease in survivors of childhood cancer: insights into epidemiology, pathophysiology, and prevention","volume":"36","author":"Sh","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lfs.2023.122377_bb0160","doi-asserted-by":"crossref","first-page":"H1091","DOI":"10.1152\/ajpheart.00312.2022","article-title":"Smad3 promotes adverse cardiovascular remodeling and dysfunction in doxorubicin-treated hearts","volume":"323","author":"Cobb","year":"2022","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122377_bb0165","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bcp.2015.08.101","article-title":"Silencing of PKC-\u03b1, TRPC1 or NF-\u03baB expression attenuates cisplatin-induced ICAM-1 expression and endothelial dysfunction","volume":"98","author":"Bodiga","year":"2015","journal-title":"Biochem. Pharmacol."},{"issue":"22","key":"10.1016\/j.lfs.2023.122377_bb0170","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1158\/0008-5472.CAN-15-3034","article-title":"Doxorubicin-induced systemic inflammation is driven by upregulation of toll-like receptor TLR4 and endotoxin leakage","volume":"76","author":"Wang","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2023.122377_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00557","article-title":"Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database","volume":"11","author":"Ceschi","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122377_bb0180","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ccr3.2601","article-title":"Coronary vasospasm induced by cisplatin for seminoma","volume":"8","author":"Sasaki","year":"2020","journal-title":"Clin. Case Rep."},{"issue":"3","key":"10.1016\/j.lfs.2023.122377_bb0185","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000455224","article-title":"Coronary spasm after an injection of vincristine","volume":"62","author":"Gros","year":"2017","journal-title":"Chemotherapy"},{"issue":"8","key":"10.1016\/j.lfs.2023.122377_bb0190","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/qjmed\/hcu184","article-title":"Arterial stiffness, endothelial dysfunction and recurrent angina post-chemotherapy","volume":"108","author":"Taniguchi","year":"2015","journal-title":"QJM"},{"issue":"5","key":"10.1016\/j.lfs.2023.122377_bb0200","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3390\/jcm11051244","article-title":"The role of vasospasm and microcirculatory dysfunction in fluoropyrimidine-induced ischemic heart disease","volume":"11","author":"Fabin","year":"2022","journal-title":"JCM"},{"issue":"1","key":"10.1016\/j.lfs.2023.122377_bb0205","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71531-8","article-title":"Activated ROCK\/Akt\/eNOS and ET-1\/ERK pathways in 5-fluorouracil-induced cardiotoxicity: modulation by simvastatin","volume":"10","author":"Muhammad","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2023.122377_bb0210","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ebiom.2017.05.024","article-title":"Spasmogenic effects of the proteasome inhibitor carfilzomib on coronary resistance, vascular tone and reactivity","volume":"21","author":"Chen-Scarabelli","year":"2017","journal-title":"EBioMedicine"},{"issue":"31","key":"10.1016\/j.lfs.2023.122377_bb0215","doi-asserted-by":"crossref","first-page":"21652","DOI":"10.1074\/jbc.M602105200","article-title":"Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function","volume":"281","author":"Wei","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.lfs.2023.122377_bb0220","first-page":"81","article-title":"Endothelin-1 and 5-fluorouracil-induced cardiotoxicity","volume":"45","author":"Porta","year":"1998","journal-title":"Neoplasma"},{"issue":"2 Pt 2","key":"10.1016\/j.lfs.2023.122377_bb0225","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/hy0202.103129","article-title":"Endothelin-1--induced enhancement of coronary smooth muscle contraction via MAPK-dependent and MAPK-independent [Ca(2+)](i) sensitization pathways","volume":"39","author":"Cain","year":"2002","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.lfs.2023.122377_bb0230","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1200\/JCO.2001.19.6.1707","article-title":"Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial","volume":"19","author":"Jassem","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122377_bb0235","first-page":"22","article-title":"Acute ST-segment elevations following paclitaxel administration for uterine cervical cancer: a case report and literature review","volume":"8","author":"Higami","year":"2022","journal-title":"Cardiooncology"},{"issue":"1","key":"10.1016\/j.lfs.2023.122377_bb0240","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0735-1097(02)02632-3","article-title":"Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm","volume":"41","author":"Mohri","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"24","key":"10.1016\/j.lfs.2023.122377_bb0245","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.jacc.2009.07.045","article-title":"Role of rho-kinase in the pathogenesis of coronary hyperconstricting responses induced by drug-eluting stents in pigs in vivo","volume":"54","author":"Shiroto","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.lfs.2023.122377_bb0250","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/01.CIR.101.11.1319","article-title":"Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta","volume":"101","author":"Kandabashi","year":"2000","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.lfs.2023.122377_bb0255","first-page":"204","article-title":"Is there a role for remote ischemic conditioning in preventing 5-fluorouracil-induced coronary vasospasm?","volume":"2","author":"Chong","year":"2019","journal-title":"Cond Med."},{"issue":"9","key":"10.1016\/j.lfs.2023.122377_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2021.100994","article-title":"AC-mode of chemotherapy as a trigger of cardiac syndrome X: a case study","volume":"47","author":"Avagimyan","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.lfs.2023.122377_bb0265","doi-asserted-by":"crossref","unstructured":"Sen F, Yildiz I, Basaran M, et al. Impaired Coronary Flow Reserve in Metastatic Cancer Patients Treated With Sunitinib. doi:https:\/\/doi.org\/10.1200\/jco.2011.29.15_suppl.e15136.","DOI":"10.1200\/jco.2011.29.15_suppl.e15136"},{"issue":"5","key":"10.1016\/j.lfs.2023.122377_bb0270","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling\u00a0? In control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.lfs.2023.122377_bb0275","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/1471-2407-12-231","article-title":"Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib","volume":"12","author":"Pantaleo","year":"2012","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.lfs.2023.122377_bb0280","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ijcard.2013.03.010","article-title":"Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safety","volume":"168","author":"Winnik","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.lfs.2023.122377_bb0285","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.vph.2017.10.004","article-title":"Axitinib attenuates intraplaque angiogenesis, haemorrhages and plaque destabilization in mice","volume":"100","author":"Van der Veken","year":"2018","journal-title":"Vascul. Pharmacol."},{"issue":"4","key":"10.1016\/j.lfs.2023.122377_bb0290","doi-asserted-by":"crossref","first-page":"460","DOI":"10.4244\/EIJV3I4A82","article-title":"First-in-man study with bevacizumab-eluting stent: a new approach for the inhibition of atheromatic plaque neovascularisation","volume":"3","author":"Stefanadis","year":"2008","journal-title":"EuroIntervention"},{"issue":"1","key":"10.1016\/j.lfs.2023.122377_bb0295","article-title":"Pro- and anti-angiogenic therapy and atherosclerosis with special emphasis on vascular endothelial growth factors","volume":"12","author":"V","year":"2012","journal-title":"Expert Opin. Biol. Therapy"},{"issue":"35","key":"10.1016\/j.lfs.2023.122377_bb0300","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lfs.2023.122377_bb0305","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1161\/01.ATV.0000128321.91782.b9","article-title":"Protective role of imatinib in atherosclerosis","volume":"24","author":"Kadowaki","year":"2004","journal-title":"ATVB"},{"issue":"2","key":"10.1016\/j.lfs.2023.122377_bb0310","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/01.TP.0000147199.60464.F9","article-title":"Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation","volume":"79","author":"Nyk\u00e4nen","year":"2005","journal-title":"Transplantation"},{"issue":"15","key":"10.1016\/j.lfs.2023.122377_bb0315","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1093\/hmg\/ddt167","article-title":"Smooth muscle hyperplasia due to loss of smooth muscle \u03b1-actin is driven by activation of focal adhesion kinase, altered p53 localization and increased levels of platelet-derived growth factor receptor-\u03b2","volume":"22","author":"Papke","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.lfs.2023.122377_bb0320","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fcvm.2018.00055","article-title":"The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model","volume":"5","author":"Pouwer","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"issue":"4","key":"10.1016\/j.lfs.2023.122377_bb0325","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.amjms.2018.11.017","article-title":"Hepatotoxicity and recurrent NSTEMI while on pembrolizumab for metastatic giant cell bone tumor","volume":"357","author":"Kwan","year":"2019","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.lfs.2023.122377_bb0330","article-title":"Possible precipitation of acute coronary syndrome with immune checkpoint blockade: a case report","volume":"24","author":"M","year":"2020","journal-title":"Permanente J."},{"issue":"9","key":"10.1016\/j.lfs.2023.122377_bb0335","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3390\/cells9091987","article-title":"Antibody-mediated inhibition of CTLA4 aggravates atherosclerotic plaque inflammation and progression in hyperlipidemic mice","volume":"9","author":"Poels","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.lfs.2023.122377_bb0340","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","article-title":"Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis","volume":"2","author":"Poels","year":"2020","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.lfs.2023.122377_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.carpath.2019.107148","article-title":"Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis","volume":"43","author":"Newman","year":"2019","journal-title":"Cardiovasc. Pathol."},{"issue":"10","key":"10.1016\/j.lfs.2023.122377_bb0350","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2010.33.7907","article-title":"Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy","volume":"30","author":"Lipshultz","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lfs.2023.122377_bb0355","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ejca.2003.12.012","article-title":"Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer","volume":"40","author":"Nuver","year":"2004","journal-title":"Eur. J. Cancer"},{"issue":"16","key":"10.1016\/j.lfs.2023.122377_bb0360","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/heartjnl-2020-317510","article-title":"Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors","volume":"107","author":"Matthews","year":"2021","journal-title":"Heart"},{"issue":"Suppl. 1","key":"10.1016\/j.lfs.2023.122377_bb0365","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1038\/sj.bjc.6602692","article-title":"The effects of aromatase inhibitors on lipids and thrombosis","volume":"93 Suppl 1","author":"Bundred","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.lfs.2023.122377_bb0370","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.juro.2009.01.047","article-title":"Metabolic complications of androgen deprivation therapy for prostate cancer","volume":"181","author":"Saylor","year":"2009","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122377_bb0375","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"JNCI J. Nat. Cancer Inst."},{"issue":"12","key":"10.1016\/j.lfs.2023.122377_bb0380","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/j.1538-7836.2007.02788.x","article-title":"Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity","volume":"5","author":"Lechner","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.lfs.2023.122377_bb0385","first-page":"1235","article-title":"Daunorubicin induces procoagulant activity of cultured endothelial cells through phosphatidylserine exposure and microparticles release","volume":"104","author":"Fu","year":"2010","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.lfs.2023.122377_bb0390","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/leu.2012.290","article-title":"The coagulopathy and thrombotic risk associated with L-Asparaginase treatment in adults with acute lymphoblastic leukaemia","volume":"27","author":"Truelove","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.lfs.2023.122377_bb0395","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm1428","article-title":"VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis","volume":"12","author":"Tam","year":"2006","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.lfs.2023.122377_bb0400","article-title":"Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice","volume":"7","author":"M","year":"2009","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.lfs.2023.122377_bb0405","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdq587","article-title":"Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes","volume":"22","author":"Schutz","year":"2011","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.lfs.2023.122377_bb0410","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","article-title":"Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis","volume":"57","author":"Chai-Adisaksopha","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.lfs.2023.122377_bb0415","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.lfs.2023.122377_bb0420","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1055\/s-0039-1688787","article-title":"Ponatinib tyrosine kinase inhibitor induces a thromboinflammatory response","volume":"119","author":"Hamadi","year":"2019","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.lfs.2023.122377_bb0425","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2016.07.019","article-title":"The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state","volume":"145","author":"Alhawiti","year":"2016","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.lfs.2023.122377_bb0430","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lfs.2023.122377_bb0435","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000501927","article-title":"Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German expert consensus panel with focus on cardiovascular management","volume":"143","author":"Saussele","year":"2020","journal-title":"Acta Haematol."},{"key":"10.1016\/j.lfs.2023.122377_bb0440","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.exphem.2018.07.008","article-title":"Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia","volume":"66","author":"Borges","year":"2018","journal-title":"Exp Hematol."},{"issue":"13","key":"10.1016\/j.lfs.2023.122377_bb0445","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jacc.2021.07.042","article-title":"Coronary microvascular dysfunction across the spectrum of cardiovascular diseases: JACC state-of-the-art review","volume":"78","author":"Del Buono","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.lfs.2023.122377_bb0450","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/eurjpc\/zwac184","article-title":"Coronary microvascular dysfunction is an independent predictor of developing cancer in patients with non-obstructive coronary artery disease","volume":"30","author":"Rajai","year":"2023","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"7","key":"10.1016\/j.lfs.2023.122377_bb0455","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1161\/CIRCRESAHA.108.172528","article-title":"Functional and structural adaptations of coronary microvessels distal to a chronic coronary artery stenosis","volume":"102","author":"Sorop","year":"2008","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.lfs.2023.122377_bb0460","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/cvr\/cvz339","article-title":"Diagnosis of coronary microvascular dysfunction in the clinic","volume":"116","author":"Ong","year":"2020","journal-title":"Cardiovasc. Res."},{"issue":"16","key":"10.1016\/j.lfs.2023.122377_bb0465","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.jcin.2020.05.052","article-title":"Assessment of vascular dysfunction in patients without obstructive coronary artery disease: why, how, and when","volume":"13","author":"Ford","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"issue":"41","key":"10.1016\/j.lfs.2023.122377_bb0470","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.lfs.2023.122377_bb0475","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.lfs.2023.122377_bb0480","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10549-021-06192-w","article-title":"Incidence of cardiotoxicity and validation of the heart failure association-international cardio-oncology society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer","volume":"188","author":"Battisti","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.lfs.2023.122377_bb0485","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.lfs.2023.122377_bb0490","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00277-020-04392-w","article-title":"Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib","volume":"100","author":"Caocci","year":"2021","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.lfs.2023.122377_bb0495","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/ehf2.13897","article-title":"The new HFA\/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity","volume":"9","author":"Di Lisi","year":"2022","journal-title":"ESC Heart Fail."},{"issue":"4","key":"10.1016\/j.lfs.2023.122377_bb0500","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41588-021-00783-5","article-title":"The polygenic score catalog as an open database for reproducibility and systematic evaluation","volume":"53","author":"Lambert","year":"2021","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.lfs.2023.122377_bb0505","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13058-021-01465-0","article-title":"Genomic risk prediction of coronary artery disease in women with breast cancer: a prospective cohort study","volume":"23","author":"Liou","year":"2021","journal-title":"Breast Cancer Res."},{"issue":"43","key":"10.1016\/j.lfs.2023.122377_bb0510","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1093\/eurheartj\/ehw450","article-title":"Genomic prediction of coronary heart disease","volume":"37","author":"Abraham","year":"2016","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.lfs.2023.122377_bb0515","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaccao.2022.04.003","article-title":"Contribution of genome-wide polygenic score to risk of coronary artery disease in childhood cancer survivors","volume":"4","author":"Sapkota","year":"2022","journal-title":"JACC CardioOncol."},{"issue":"5","key":"10.1016\/j.lfs.2023.122377_bb0520","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jaccao.2021.09.010","article-title":"Cardiac computed tomography in cardio-oncology: JACC: cardioOncology primer","volume":"3","author":"Lopez-Mattei","year":"2021","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.lfs.2023.122377_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2020.100119","article-title":"Association between coronary artery calcium and cardiovascular disease as a supporting cause in cancer: the CAC consortium","volume":"4","author":"Wang","year":"2020","journal-title":"Am. J. Prev. Cardiol."},{"issue":"17","key":"10.1016\/j.lfs.2023.122377_bb0530","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/eurjpc\/zwac185","article-title":"Incidental coronary calcium in cancer patients treated with anthracycline and\/or trastuzumab","volume":"29","author":"Hooks","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"5","key":"10.1016\/j.lfs.2023.122377_bb0535","first-page":"E202","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter. Cardiovasc. Interv."},{"issue":"22","key":"10.1016\/j.lfs.2023.122377_bb0540","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.lfs.2023.122377_bb0545","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001032","article-title":"Future perspectives of cardiovascular biomarker utilization in cancer survivors: a scientific statement from the american heart association","volume":"144","author":"Zaha","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2023.122377_bb0550","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejca.2021.06.021","article-title":"Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: a systematic review and recommendations from the international late effects of childhood Cancer guideline harmonization group","volume":"156","author":"van Dalen","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.lfs.2023.122377_bb0555","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","article-title":"Permissive cardiotoxicity: the clinical crucible of cardio-oncology","volume":"4","author":"Porter","year":"2022","journal-title":"JACC CardioOncol."},{"issue":"8","key":"10.1016\/j.lfs.2023.122377_bb0560","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2022.12138","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US preventive services task force","volume":"328","author":"Chou","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.lfs.2023.122377_bb0565","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13058-018-1066-z","article-title":"Statin drugs to reduce breast cancer recurrence and mortality","volume":"20","author":"Beckwitt","year":"2018","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.lfs.2023.122377_bb0570","doi-asserted-by":"crossref","first-page":"89","DOI":"10.15420\/icr.2019.12","article-title":"Coronary artery vasospasm induced by 5-fluorouracil: proposed mechanisms, existing management options and future directions","volume":"14","author":"Chong","year":"2019","journal-title":"Interv. Cardiol."},{"issue":"3","key":"10.1016\/j.lfs.2023.122377_bb0575","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"K","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.lfs.2023.122377_bb0580","doi-asserted-by":"crossref","DOI":"10.1007\/s10741-023-10328-z","article-title":"ACEI\/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis","author":"Gao","year":"2023","journal-title":"Heart Fail. Rev."},{"issue":"7","key":"10.1016\/j.lfs.2023.122377_bb0585","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/clc.22007","article-title":"Treatment and outcomes of acute coronary syndrome in the cancer population","volume":"35","author":"Yusuf","year":"2012","journal-title":"Clin. Cardiol."},{"issue":"24","key":"10.1016\/j.lfs.2023.122377_bb0590","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO.2017.72.3569","article-title":"Timing of aspirin and other nonsteroidal anti-inflammatory drug use among patients with colorectal cancer in relation to tumor markers and survival","volume":"35","author":"Hua","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.lfs.2023.122377_bb0595","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1056\/NEJMoa1207756","article-title":"Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival","volume":"367","author":"Liao","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lfs.2023.122377_bb0600","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.lfs.2023.122377_bb0605","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.lfs.2023.122377_bb0610","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000750","article-title":"EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer","volume":"6","author":"Falanga","year":"2022","journal-title":"Hemasphere"},{"issue":"47","key":"10.1016\/j.lfs.2023.122377_bb0615","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1093\/eurheartj\/ehx531","article-title":"The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum","volume":"38","author":"McCarthy","year":"2017","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.lfs.2023.122377_bb0620","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188740","article-title":"Clopidogrel in a combined therapy with anticancer drugs-effect on tumor growth, metastasis, and treatment toxicity: studies in animal models","volume":"12","author":"Denslow","year":"2017","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.lfs.2023.122377_bb0625","first-page":"829","article-title":"Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis","volume":"10","author":"Mohamed","year":"2021","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"2","key":"10.1016\/j.lfs.2023.122377_bb0630","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00432-015-2056-5","article-title":"Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period","volume":"142","author":"Guddati","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.lfs.2023.122377_bb0635","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2017.08.015","article-title":"\u201cBringing on the light\u201d in a complex clinical scenario: optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry)","volume":"194","author":"Iliescu","year":"2017","journal-title":"Am. Heart J."},{"issue":"4","key":"10.1016\/j.lfs.2023.122377_bb0640","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaccao.2023.05.008","article-title":"Cardiac interventions in patients with active, advanced solid and hematologic malignancies","volume":"5","author":"Leong","year":"2023","journal-title":"JACC CardioOncol."},{"issue":"3","key":"10.1016\/j.lfs.2023.122377_bb0645","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/ejcts\/ezaa114","article-title":"Coronary artery bypass grafting in patients with concomitant solid tumours: early and long-term results","volume":"58","author":"Garatti","year":"2020","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"22","key":"10.1016\/j.lfs.2023.122377_bb0650","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/eurheartj\/ehy769","article-title":"Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States","volume":"40","author":"Potts","year":"2019","journal-title":"Eur. Heart J."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320523010123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320523010123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:12:33Z","timestamp":1758402753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320523010123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":129,"alternative-id":["S0024320523010123"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2023.122377","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of chemotherapy in tumor on coronary arteries: Mechanisms and management","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2023.122377","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"122377"}}